These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 4742916)

  • 1. Comparative blood levels and metabolism of INH and an INH-matrix preparation in fast and slow inactivators.
    Jeanes CW; Schaefer O; Eidus L
    Can Med Assoc J; 1973 Sep; 109(6):483-7. PubMed ID: 4742916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new isoniazid preparation designed for moderately fast and "fast" metabolizers of the drug.
    Eidus L; Hodgkin MM
    Arzneimittelforschung; 1975 Jul; 25(7):1077-80. PubMed ID: 1101901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained release isoniazid tablets. I--Formulation and in vitro evaluation.
    Bulut-Oner F; Capan Y; Kas S; Oner L; Hincal AA
    Farmaco; 1989; 44(7-8):739-52. PubMed ID: 2590371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of various isoniazid slow releasing matrix preparations for intermittent chemotherapy of tuberculosis.
    Hodgkin MM; Eidus L; Hershfield ES
    Res Commun Chem Pathol Pharmacol; 1979 May; 24(2):349-65. PubMed ID: 461989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Type of isoniazid (INH) acetylation determined in tuberculosis patients treated at the Institute of Tuberculosis and Lung Diseases in Warsaw during the years 1990-1997].
    Augustynowicz-Kopeć E; Zwolska Z
    Pneumonol Alergol Pol; 2002; 70(3-4):180-92. PubMed ID: 12271965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of serial plasma Isoniazid concentrations with different doses of a slow-release preparation of Isoniazid.
    Sarma GR; Kailasam S; Mitchison DA; Nair NG; Radhakrishna S; Tripathy SP
    Tubercle; 1975 Dec; 56(4):314-23. PubMed ID: 779186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.
    Jung JA; Kim TE; Lee H; Jeong BH; Park HY; Jeon K; Kwon OJ; Ko JW; Choi R; Woo HI; Koh WJ; Lee SY
    Drug Des Devel Ther; 2015; 9():5433-8. PubMed ID: 26491254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Further studies on the pharmacology of a slow-release matrix preparation of isoniazid (Smith and Nephew HS 82) of potential use in the intermittent treatment of tuberculosis.
    Ellard GA; Gammon PT; Polansky F; Víznerová A; Havlík I; Fox W
    Tubercle; 1973 Mar; 54(1):57-66. PubMed ID: 4774935
    [No Abstract]   [Full Text] [Related]  

  • 9. Isoniazid acetylator status of Black South African tuberculosis patients.
    Bach PH; Higgins-Opitz SB; Bima B; Leary WP
    S Afr Med J; 1976 Jul; 50(29):1132-4. PubMed ID: 959925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bioavailability of isoniazid in healthy volunteers--fast and slow INH acetylators].
    Augustynowicz-Kopeć E; Zwolska Z; Niemirowska-Mikulska H
    Pneumonol Alergol Pol; 2002; 70(3-4):167-79. PubMed ID: 12271964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The type of isoniazid acetylation in tuberculosis patients treated at National Tuberculosis and Lung Diseases Research Institute.
    Augustynowicz-Kopeć E; Zwolska Z
    Acta Pol Pharm; 2002; 59(6):443-7. PubMed ID: 12669768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The pharmacokinetics of isoniazid in children (author's transl)].
    Advenier C; Saint-Aubin A; Scheinmann P; Paupe J
    Rev Fr Mal Respir; 1981; 9(5):365-74. PubMed ID: 7323401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the acetylator phenotype using matrix isoniazid.
    Ellard GA; Gammon PT; Titinen H
    Tubercle; 1975 Sep; 56(3):203-9. PubMed ID: 1216339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of isoniazid bioavailability in normal men by concomitant intake of food.
    Melander A; Danielson K; Hanson A; Jansson L; Rerup JC; Scherstén B; Thulin T; Wåhlin E
    Acta Med Scand; 1976; 200(1-2):93-97. PubMed ID: 961472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of isoniazid phenotyping of black and white patients with emphasis on South African blacks.
    Eidus L; Glatthaar E; Hodgkin MM; Nel EE; Kleeberg HH
    Int J Clin Pharmacol Biopharm; 1979 Jul; 17(7):311-6. PubMed ID: 489198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.
    Schaaf HS; Parkin DP; Seifart HI; Werely CJ; Hesseling PB; van Helden PD; Maritz JS; Donald PR
    Arch Dis Child; 2005 Jun; 90(6):614-8. PubMed ID: 15908628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of a method of analysis using high performance liquid chromatography of isoniazid and acetylisoniazid to determine the phenotype of acetylation].
    Miscoria G; Leneveu A; Walle C; Roux A
    Ann Biol Clin (Paris); 1988; 46(9):734-40. PubMed ID: 3223632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailored release drug delivery system for rifampicin and isoniazid for enhanced bioavailability of rifampicin.
    Avachat AM; Bhise SB
    Pharm Dev Technol; 2011 Apr; 16(2):127-36. PubMed ID: 20105081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levels of acetyl hydrazines and rate of acetylation of isoniazid in adult tuberculosis patients.
    Bhalerao EB; Bhide SV
    Indian J Physiol Pharmacol; 1985; 29(2):83-8. PubMed ID: 4093196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CLINICAL STUDY OF ISONIAZID INACTIVATION.
    JESSAMINE AG; HAMILTON EJ; EIDUS L
    Can Med Assoc J; 1963 Dec; 89(24):1214-7. PubMed ID: 14084700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.